HexemBio is developing regenerative therapies based on the Synthetic Human Yolk Sac, a technology designed to rejuvenate aging blood stem cells by recreating the developmental environment where they first arise. By restoring the regenerative capacity of a patient's own hematopoietic stem cells, HexemBio aims to improve outcomes in bone marrow transplantation and unlock new approaches to extending human healthspan. The company received FDA Orphan Drug Designation in July 2025 and completed its FDA Pre-IND meeting in January 2026. Founded in 2024, HexemBio operates from New York City and from Berkeley. To learn more, visit hexemb.io.
| Website | https://www.hexemb.io/ |
| Employees | 12 (6 on RocketReach) |
| Founded | 2024 |
| Address | 7 Pennsylvania Plaza Floor 9, New York, New York 10001, US |
| Industry | Biotechnology Research |
Looking for a particular HexemBio employee's phone or email?
HexemBio Questions
Gabriel Tremblay is the CEO and Co-Founder of HexemBio.
6 people are employed at HexemBio.
HexemBio is based in New York, New York.
Top HexemBio Employees
-
Gabriel Tremblay
CEO and Co-Founder at HexemBio
New York, NY, US35+ -
Samet Yildirim
Co-Founder and Chief Business Officer at HexemBio
San Francisco, CA, US34 -
Samira Kiani
CTO and Cofounder at HexemBio
Tiburon, CA, US31 -
Joshua Hislop
Co-Founder and AI Lead at HexemBio
Pittsburgh, PA, US1 -
Jeff Stogsdill
Principal Scientist at HexemBio
Cambridge, MA, US11 -
Inna Dolinskiy
Research Associate Intern at HexemBio
Berkeley, CA, US
